Contents

Section Editors / vii
Contributors / xi
Preface / xxix
A Note about Terminology / xxxi
Acknowledgments / xxxiii

SECTION 1 Section Editor: Kevin Kunz, MD
Basic Science and Core Concepts / 1

1 Drug Addiction: The Neurobiology of Behavior Gone Awry / 3
   Nora D. Volkow, MD and Kenneth R. Warren, PhD

2 The Epidemiology of Substance Use Disorders / 19
   Rosa M. Crum, MD, MHS

3 The Anatomy of Addiction / 36
   Thomas J.R. Beveridge, PhD
   and David C.S. Roberts, PhD

4 From Neurobiology to Treatment: Progress Against Addiction / 49
   Eric J. Nestler, MD, PhD

5 Understanding “Behavioral Addictions”: Insights from Research / 55
   Yvonne H.C. Yau, MSc, Sarah W. Yip, MSc, PhD,
   and Marc N. Potenza, MD, PhD

SECTION 2 Section Editors: Thomas R. Kosten, MD, PhD,
   David A. Gorelick, MD, PhD, and John A. Dani, PhD
Pharmacology / 83

6 Pharmacokinetic and Pharmacodynamic Principles / 85
   Anne Zajicek, MD, PharmD, FAAP and
   Lori D. Karan, MD, FACP, FASAM

7 The Pharmacology of Alcohol / 100
   John J. Woodward, BS, MS, PhD

8 The Pharmacology of Nonalcohol Sedative Hypnotics / 117
   Domenic A. Ciraulo, MD and Clifford M. Knapp, PhD

SIDEBAR: GHB / 128
   Reshmi Pal, MD, MPH, John Mendelson, MD,
   and Gantt P. Galloway, PharmD

9 The Pharmacology of Opioids / 135
   Lisa Borg, MD, Michele Buonora, BS, Eduardo R.
   Butelman, PhD, Elizabeth Ducat, ANP, Brenda M.
   Ray, MS, MPH, FNP-BC, and Mary Jeanne Kreek, MD

10 The Pharmacology of Cocaine, Amphetamines, and Other Stimulants / 151
   David A. Gorelick, MD, PhD
   and Michael H. Baumann, PhD

   SIDEBAR: Psychoactive "Bath Salts": A New Class of Designer Stimulants / 171
   Michael H. Baumann, PhD and Kurt R. Lehner, BS

11 The Pharmacology of Caffeine / 180
   Laura M. Juliano, PhD, Sergi Ferré, MD, PhD, and
   Roland R. Griffiths, PhD

12 The Pharmacology of Nicotine and Tobacco / 201
   John A. Dani, PhD, Thomas R. Kosten, MD, PhD,
   and Neal L. Benowitz, MD

13 The Pharmacology of Marijuana / 217
   Sandra P. Welch, PhD and Robert Malcolm, MD

14 The Pharmacology of Hallucinogens / 235
   Torsten Passie, MD, MA and John H. Halpern, MD

15 The Pharmacology of Dissociatives / 256
   Edward F. Domino, IMS, MD and Shannon C. Miller,
   MD, FASAM, DFAPA

16 The Pharmacology of Inhalants / 267
   Robert L. Balster, PhD

   SIDEBAR: Inhalant Abuse in the Military / 275
   Robert L. Balster, PhD

17 The Pharmacology of Anabolic–Androgenic Steroids / 277
   Scott E. Lukas, PhD

   SIDEBAR: Accessing Information on Newly Emerging Drugs of Abuse / 288
   Barbara M. Kirrane, MD, MPH
   and Gail D’Onofrio, MD, MS
SECTION 3  Section Editor: Theodore V. Parran, Jr., MD, FACP

Diagnosis, Assessment, and Early Intervention / 295

18 Screening and Brief Intervention / 297
Aleksandra Zgierska, MD, PhD
and Michael F. Fleming, MD, MPH

SIDEBAR: Screening and Brief Intervention for Pregnant Women / 312
Nicolas Bertholet, MD, MSc
and Richard Saitz, MD, MPH, FACP, FASAM

SIDEBAR: Trauma Centers, Hospitals, and Emergency Departments / 317
Richard D. Blondell, MD

SIDEBAR: Implementation of Screening and Brief Intervention in Clinical Settings Using Quality Improvement Principles / 321
Katharine A. Bradley, MD, MPH
and Emily C. Williams, PhD, MPH

SIDEBAR: Screening for Unhealthy Alcohol Use in the Elderly / 326
James W. Campbell, MD, MS

19 Laboratory Diagnosis / 332
Elizabeth Warner, MD and Emily Lorch, MD

20 Assessment / 344
Theodore V. Parran, Jr., MD, FACP, Richard A. McCormick, PhD, and Christina M. Delos Reyes, MD

21 Environmental Approaches to Prevention: A Community-Based Perspective / 353
Andrew J. Treno, PhD, Paul J. Gruenewald, PhD, Joel W. Grube, AB, MS, PhD, Robert F. Saltz, PhD, and Mallie J. Paschal, PhD

SECTION 4  Section Editors: Wilson M. Compton, MD, MPE†

Overview of Addiction Treatment / 363

22 Addiction Medicine in America: Its Birth and Early History (1750–1935) with a Modern Postscript / 365
William L. White, MA and James F. Callahan, DPA

23 Treatment of Heavy Drinking and Alcohol Use Disorder / 375
Mark L. Willenbring, MD

24 The Treatment of Drug Addiction: An Overview / 389
Andrea G. Barthwell, MD, FASAM and
Lawrence S. Brown Jr., MD, MPH, FASAM

25 Moving Toward Integrated Care for Substance Use Disorders: Lessons from History and the Rest of Health Care / 403
A. Thomas McLellan, PhD

26 Effects of Treatment Setting, Duration, and Amount on Patient Outcomes / 418
John W. Finney, PhD, Rudolf H. Moos, PhD, and Paula L. Wilbourne, PhD

27 The ASAM Criteria and Matching Patients to Treatment / 428
David Mee-Lee, MD and Gerald D. Shulman, MA, MAC, FACATA

28 Linking Addiction Treatment with Other Medical and Psychiatric Treatment Systems / 442
Karran A. Phillips, MD, MSc, Peter D. Friedmann, MD, MPH, FASAM, FACP, Richard Saitz, MD, MPH, FACP, FASAM, and Jeffrey H. Samet, MD, MA, MPH

29 Alternative Therapies for Alcohol and Drug Addiction / 456
David Y-W Lee, PhD

30 The Harm Reduction Approach to Prevention and Treatment / 466
Alex Wodak, MD, MBBS, FRACP, FACHAM

SIDEBAR: A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs / 475
Angela K. Clark, MSN, RN, Christine M. Wilder, MD, and Erin L. Winstanley, PhD

31 Quality Improvement for Addiction Treatment / 480
James H. Ford II, PhD, Kim A. Hoffman, PhD, and Kimberly Johnson, MBA

32 Nursing Roles in Addressing Addiction / 493
Marianne T. Marcus, EdD, RN, FAAN, Christine Savage, PhD, RN, CARN, FAAN, and Deborah S. Finnell, DNS, PHMHNP-BC, CARN-AP, FAAN

33 International Perspectives on Addiction Management / 501
Nady el-Guebaly, MD, DPsysch, DPH, FRCP, DABAM, Vladimir Poznyak, MD, PhD, and Juana M. Tomás-Rosselló, MD, MPH

†Chapters 24, 26, 27, 29, and 33
SECTION 5  Section Editors: Joan E. Zweben, PhD and Peter Banys, MD, MSc

Special Issues in Addiction / 511

34 Nonmedical Use, Misuse, and Abuse of Prescription Medications / 513
Martha J. Wunsch, MD, FAAP, FASAM, Pamela K. Gonzalez, MD, MS, FAAP, John A. Hopper, MD, FAAP, FACP, FASAM, Mary G. McMasters, MD, FASAM, and Carol J. Boyd, PhD, MSN, RN, FAAN

35 Special Issues in Treatment: Women / 524
Joan E. Zweben, PhD

SIDEBAR: Military Sexual Trauma / 535
Joan E. Zweben, PhD

36 Treatment of Older Adults / 541
Frederic C. Blow, PhD and Kristen L. Barry, PhD

37 Cultural Issues in Addiction Medicine / 555
Joseph J. Westermeyer, MD, MPH, PhD and Marion Warwick, MD, MPH

38 College Student Drinking / 562
Ursula Whiteside, PhD, Joyce N. Bittinger, PhD, Jason R. Kilmer, PhD, Ty W. Lostutter, PhD, and Mary E. Larimer, PhD

39 Pathologic Gambling: Clinical Characteristics and Treatment / 575
Jon E. Grant, MD, JD, MPH, Brian L. Odlaug, MPH, and Liana R.N. Schreiber, BA

40 Sexual Addiction / 588
Steven J. Shoptaw, PhD and Matthew Brensilver, PhD

41 Physician Health Programs and Addiction among Physicians / 602
Paul H. Earley, MD, FASAM

SECTION 6  Section Editor: Adam J. Gordon, MD, MPH, FACP, FASFM

Management of Intoxication and Withdrawal / 623

42 Management of Intoxication and Withdrawal: General Principles / 625
Tara M. Wright, MD, Jeffrey S. Cluver, MD, and Hugh Myrick, MD

43 Management of Alcohol Intoxication and Withdrawal / 635
Alan A. Wartenberg, MD, FACP, FASAM

44 Management of Sedative–Hypnotic Intoxication and Withdrawal / 652
William E. Dickinson, DO, FASAM, FAAFP, ABAM, and Steven J. Eickelberg, MD, FASAM

45 Management of Opioid Intoxication and Withdrawal / 668
Jeanette M. Tetrault, MD, FACP and Patrick G. O’Connor, MD, MPH

46 Management of Stimulant, Hallucinogen, Marijuana, Phencyclidine, and Club Drug Intoxication and Withdrawal / 685
Jeffery N. Wilkins, MD, FASAM, DFAPA, Itai Danovitch, MD, MBA, and David A. Gorelick, MD, PhD

SECTION 7  Section Editor: Andrew J. Saxon, MD

Pharmacologic Interventions / 711

47 Medications for Use in Alcohol Rehabilitation / 713
Hugh Myrick, MD, Henry R. Kranzler, MD, Domenic A. Ciraulo, MD, Andrew J. Saxon, MD, and Jerome H. Jaffe, MD

48 Pharmacologic Intervention for Sedative–Hypnotic Addiction / 727
Jeffrey S. Cluver, MD, Tara M. Wright, MD, and Hugh Myrick, MD

49 Pharmacologic Interventions for Opioid Dependence / 735
Susan M. Stine, MD, PhD and Thomas R. Kosten, MD, PhD

50 Opioid Maintenance Treatment / 759
Judith Martin, MD, Joan E. Zweben, PhD and J. Thomas Payte, MD

51 Special Issues in Office-Based Opioid Treatment / 778
Andrew J. Saxon, MD

52 Pharmacologic Interventions for Cocaine, Methamphetamine, and Other Stimulant Addiction / 796
David A. Gorelick, MD, PhD

53 Pharmacologic Interventions for Tobacco Dependence / 811
Richard D. Hurt, MD, FASAM, Jon O. Ebbert, MD, J. Taylor Hays, MD, and David D. McFadden, MD

54 Pharmacologic Interventions for Other Drug and Multiple Drug Addictions / 823
Jeffery N. Wilkins, MD, FASAM, DFAPA, Mark Hrymoc, MD, and David A. Gorelick, MD, PhD
SECTION 8  Section Editor: Richard N. Rosenthal, MD
Behavioral Interventions / 831

55 Enhancing Motivation to Change / 833
James O. Prochaska, PhD

56 Group Therapies / 845
Dennis C. Daley, PhD, Antoine Douaihy, MD, Roger D. Weiss, MD, and Delinda E. Mercer, PhD

57 Individual Treatment / 858
Deborah L. Haller, PhD and Edward V. Nunes, MD

58 Contingency Management and the Community Reinforcement Approach / 877
Stephen T. Higgins, PhD, Ryan Redner, PhD, and Thomas J. White, PhD

59 Behavioral Interventions in Smoking Cessation / 894
Christopher W. Kahler, PhD, Erika Litvin Bloom, PhD, Adam M. Leventhal, PhD, and Richard A. Brown, PhD

60 Network Therapy / 912
Marc Galanter, MD and Helen Dermatis, PhD

61 Therapeutic Communities / 923
Donald J. Kurth, MD, MBA, MPA, FASAM

SIDEBAR: Overview of Therapeutic Community Outcome Research / 933
Stanley Sacks, PhD

SIDEBAR: Modified Therapeutic Community for Persons with Co-Occurring Mental and Substance Use Disorders / 936
Stanley Sacks, PhD

62 Aversion Therapies / 944
P. Joseph Frawley, MD and Matthew O. Howard, MD

63 Family Involvement in Addiction, Treatment, and Recovery / 958
Michael R. Liepman, MD, DFAPA, FASAM, Kathleen A. Gross, MD, Maritza M. Lagos, MD, DABAM, Theodore V. Parran, Jr, MD, FACP, and Kathleen J. Farkas, PhD, LISW, ACSW

64 Twelve-Step Facilitation Approaches / 975
Kathleen M. Carroll, PhD

65 Microprocessor Abuse and Internet Addiction / 980
Richard N. Rosenthal, MD and Zebulon Taintor, MD

66 Relapse Prevention: Clinical Models and Intervention Strategies / 991
Antoine Douaihy, MD, Dennis C. Daley, PhD, G. Alan Marlatt, PhD, and Dennis M. Donovan, PhD

67 Medical Management Techniques and Collaborative Care: Integrating Behavioral with Pharmacologic Interventions in Addiction Treatment / 1008
Richard N. Rosenthal, MD, Richard K. Ries, PhD, and Joan E. Zweben, PhD

68 Conceptual and Treatment Issues in “Behavioral Addictions” / 1024
Abigail J. Herron, DO, Paul Rinaldi, PhD, and Petros Levounis, MD, MA

SECTION 9  Section Editor: Marc Galanter, MD, FASAM
Mutual Help, Twelve Step, and Other Recovery Programs / 1031

69 Twelve-Step Programs in Addiction Recovery / 1033
Edgar P. Nace, MD

70 Recent Research into Twelve-Step Programs / 1043
Barbara S. McCrady, PhD and J. Scott Tonigan, PhD

71 Spirituality in the Recovery Process / 1060
Marc Galanter, MD

SECTION 10  Section Editors: Jeanette M. Tetrault, MD, FACP and Patrick G. O’Connor, MD, MPH
Medical Disorders and Complications of Addiction / 1065

72 Medical and Surgical Complications of Addiction / 1067
Richard Saitz, MD, MPH, FACP, FASAM

73 Cardiovascular Consequences of Alcohol and Other Drug Use / 1090
Steven Pfau, MD and Howard S. Friedman, MD

74 Liver Disorders Related to Alcohol and Other Drug Use / 1106
Paul S. Haber, MD, FRACP, FAcHAMS, Robert G. Batey, MD, FRACP, FRCP(UK), FAcHAMS, and Sara E. Mgaith, MBBS, FRACP

75 Renal and Metabolic Disorders Related to Alcohol and Other Drug Use / 1133
Stanley D. Crittenden, MD and Jeffrey I. Silberzweig, MD
76  Gastrointestinal Disorders Related to Alcohol and Other Drug Use / 1145
   Paul S. Haber, MD, FRACP, FACHAM

77  Respiratory Tract Disorders Related to Alcohol and Other Drug Use / 1157
   Jason J. Heavner, MD, Jussi J. Saukkonen, MD, and Kathleen M. Akgün, MD

78  Neurologic Disorders Related to Alcohol and Other Drug Use / 1178
   Jason J. Sico, MD, Hardik Amin, MD, Anna Sorokin, MD, Darren C. Volpe, MD, Hamada Hamid, DO, MPH, Duarte Machado, MD, Huned S. Patwa, MD, and John C.M. Brust, MD

79  Human Immunodeficiency Virus, Tuberculosis, and Other Infectious Diseases Related to Alcohol and Other Drug Use / 1195
   Carol A. Sulis

80  Sleep Disorders Related to Alcohol and Other Drug Use / 1216
   Sanford Auerbach, MD

81  Traumatic Injuries Related to Alcohol and Other Drug Use: Epidemiology, Screening, and Prevention / 1231
   Federico E. Vaca, MD, MPH, FACEP and Gail D’Onofrio, MD, MS

82  Endocrine and Reproductive Disorders Related to Alcohol and Other Drug Use / 1239
   Alan Ona Malabanan, MD, FACE

83  Alcohol and Other Drug Use during Pregnancy: Management of the Mother and Child / 1254
   Michael F. Weaver, MD, FASAM, Hendrée E. Jones, PhD, and Martha J. Wunsch, MD, FAAP, FASAM

84  Surgical Interventions in the Alcohol- or Drug-Using Patient / 1272
   Daniel P. Alford, MD, MPH, FACP, FASAM

85  Substance-Induced Mental Disorders / 1287
   Christine Yuodelis-Flores, MD, R. Jeffrey Goldsmith, MD, and Richard K. Ries, MD, FAPA, FASAM

86  Co-Occurring Addictive and Mood Disorders / 1300
   Edward V. Nunes, MD and Roger D. Weiss, MD

87  Co-Occurring Addiction and Anxiety Disorders / 1333
   Karen J. Hartwell, MD, Todd K. Magro, MD, and Kathleen T. Brady, MD, PhD

88  Co-Occurring Addiction and Psychotic Disorders / 1346
   Douglas Ziedonis, MD, MPH, Xiaoduo Fan, MD, MPH, MS, Aurelia N. Bizamcer, MD, PhD, Stephen A. Wyatt, DO, Makenzie E. Tonelli, BA, and David A. Smelson, PsyD

89  Co-Occurring Addictive Disorder and Attention Deficit Hyperactivity Disorder / 1365
   Frances Rudnick Levin, MD and John J. Mariani, MD

90  Co-Occurring Personality Disorders and Addiction / 1385
   Stephen Ross, MD, Jeffrey R. Guss, MD, and Erin Zerbo, MD

91  Posttraumatic Stress Disorder and Substance Use Disorder Comorbidity / 1403
   Michael E. Saladin, PhD, Sudie E. Back, PhD, Rebecca A. Payne, MD, Jeremiah Schumm, PhD, R. Jeffrey Goldsmith, MD, and Kathleen M. Chard, PhD

92  Co-Occurring Addiction and Eating Disorders / 1418
   Lisa J. Merlo, PhD, MPE, Kevin Wandler, MD, and Mark S. Gold, MD, FASAM

SECTION 12  Section Editors: Edward C. Covington, MD, Margaret M. Kotz, DO, and Seddon R. Savage, MD, MS, FASAM

Pain and Addiction / 1433

93  The Pathophysiology of Chronic Pain and Clinical Interfaces with Addiction / 1435
   Rollin M. Gallagher, MD, MPH, George Koob, PhD, and Adrian Popescu, MD

94  Psychological Issues in the Management of Pain / 1457
   Edward C. Covington, MD and Margaret M. Kotz, DO

95  Rehabilitation Approaches to Pain Management / 1480
   Steven Stanos, DO and Randy L. Calisoff, MD
CONTENTS

SECTION 13  Section Editors: Deborah R. Simkin, MD, John R. Knight, MD, and Ramon Solhkhah, MD

Children and Adolescents / 1553

100 Epidemiology of Adolescent Substance Use / 1555
  Melissa Weddle, MD, MPH and Patricia K. Kokotailo, MD, MPH

SIDEBAR: Adolescents’ Attitudes toward Alcohol and Other Drugs / 1563
  Melissa Weddle, MD, MPH and Patricia K. Kokotailo, MD, MPH

SIDEBAR: Medical Marijuana Policy and Youth / 1564
  Sion K. Harris, PhD, CPH, Julie K. Johnson, MA, and John R. Knight, MD

101 Preventing Substance Use among Children and Adolescents / 1572
  Kenneth W. Griffin, PhD, MPH and Gilbert J. Botvin, PhD

102 Neurobiology of Addiction from a Developmental Perspective / 1580
  Deborah R. Simkin, MD

103 Screening and Brief Intervention for Adolescents / 1601
  Traci L. Brooks, MD and John R. Knight, MD

104 Assessing Adolescent Substance Use / 1609
  Ken C. Winters, PhD, Tamara Fahnhorst, MPH, Andria Botzet, MA, Ali Nicholson, BS, and Randy Stinchfield, PhD

105 Placement Criteria and Strategies for Adolescent Treatment Matching / 1627
  Marc Fishman, MD

SIDEBAR: Confidentiality in Dealing with Adolescents / 1639
  Alain Joffe, MD, MPH and Margaret R. Moon, MD, MPH

SIDEBAR: Drug Testing Adolescents in School / 1642
  J. Wesley Boyd, MD, PhD and John R. Knight, MD

106 Adolescent Treatment and Relapse Prevention / 1647
  Steven L. Jaffe, MD, Ashraf Attalla, MD, and Diana J. Simeonova, Dipl-Psych, PhD

107 Pharmacotherapy for Adolescents with Substance Use Disorders / 1656
  Lisa A. Marsch, PhD and Geetha Subramaniam, MD

108 Co-Occurring Psychiatric Disorders in Adolescents / 1666
  Ramon Solhkhah, MD and Muhammad Abbas, MD

SIDEBAR: Confidentiality in Dealing with Adolescents / 1639
  Alain Joffe, MD, MPH and Margaret R. Moon, MD, MPH

SIDEBAR: Drug Testing Adolescents in School / 1642
  J. Wesley Boyd, MD, PhD and John R. Knight, MD

SECTION 14  Section Editors: Bonnie B. Wilford, MS and Robert L. DuPont, MD, FASAM

Ethical, Legal, and Liability Issues in Addiction Practice / 1683

109 Ethical Issues in Addiction Practice / 1685
  H. Westley Clark, MD, JD, MPH, CAS, FASAM, Anton C. Bizzell, MD, and Anthony Campbell, RPh, DO

110 Consent and Confidentiality Issues in Addiction Practice / 1694
  Louis E. Baxter, Sr., MD, FASAM, Robert J. Conroy, Esq, and Bonnie B. Wilford, MS

111 Clinical, Ethical, and Legal Considerations in Prescribing Drugs with Abuse Potential / 1703
  James W. Finch, MD, Theodore V. Parran, Jr., MD, FACP, Bonnie B. Wilford, MS, and Stephen A. Wyatt, DO

SIDEBAR: Drug Control Policy: History and Future Directions / 1711
  Robert L. DuPont, MD, FASAM and John J. Coleman, PhD

112 The Science and Clinical Uses of Drug Testing / 1717
  Robert L. DuPont, MD, FASAM, Bruce A. Goldberger, PhD, DABFT, and Mark S. Gold, MD, FASAM

SIDEBAR: Workplace Drug Testing and the Role of the Medical Review Officer / 1725
  Robert L. Dupont, MD, FASAM and James L. Ferguson, DO, FASAM
113 Drug Treatment Courts and the Treatment of Persons in the Criminal Justice System / 1730
The Hon. Peggy Fulton Hora, JD (Ret.)

SIDEBAR: Therapeutic Jurisprudence / 1735
Bruce J. Winick, JD and David B. Wexler, JD

SIDEBAR: Treatment of Individuals in the Criminal Justice Population / 1737
Lori D. Karan, MD, FACP, FASAM and Randall T. Brown, MD, PhD, FASAM

114 Preventing and Treating Substance Use Disorders in Military Personnel / 1743
David C. Lewis, MD, Rhonda Robinson Beale, MD, Mathea Falco, JD, Dennis McCarty, PhD, Charles P. O’Brien, MD, PhD, and Constance Weisner, DrPH, MSW

SIDEBAR: Risk Factors for Military Families / 1750
Joan E. Zweben, PhD and Susan Storti, PhD, RN, CARN-AP

Appendices†

Section Editor: Bonnie B. Wilford, MS

Appendix 1. ASAM Addiction Terminology

Appendix 2. Screening and Assessment Instruments

Appendix 3. Crosswalks of the The ASAM Criteria: Treatment Criteria for Substance-Related, Addictive and Co-Occurring Conditions

Appendix 4. Summary of the DSM-5 Diagnostic Criteria

Appendix 5. Summary of the ICD Coding Designations

Appendix 6. Federal Schedules of Controlled Drugs

Appendix 7. Federation of State Medical Boards Model Policy on Office-Based Opioid Treatment (OBOT)

Appendix 8. Federation of State Medical Boards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain

Index / 1757

†Appendices can be found in the accompanying eBook version.